Results 241 to 250 of about 64,689 (285)

A Model of Hospital Patient Engagement for Value Co‐Creation: Does It Affect Performance? A U.S. Hospital Industry Study

open access: yesJournal of Operations Management, EarlyView.
ABSTRACT A holistic model encompassing a hospital patient engagement system and its relationship to the quality of provider‐patient interactions is presented. Based on service‐dominant logic, the study examined whether the effects on hospital performance of providers' systemic patient engagement efforts to enable value co‐creation are fully mediated by
Shawnee K. Vickery   +3 more
wiley   +1 more source

Bee products as alternatives in the treatment of viral infections

open access: yesJournal of the Science of Food and Agriculture, EarlyView.
Abstract Medicines used in the treatment of viral infections usually reduce symptoms. There is a need to develop drugs that inhibit the viruses and do not merely relieve the symptoms. Natural bee products possess many pharmacological properties and are widely used in folk medicine. There are many studies on the antibacterial effects of bee products but
Michał Otręba   +3 more
wiley   +1 more source

Foot-and-mouth disease virus vaccine with VP1 G-H loop substitution of the Cathay strain broadens antigen spectrum. [PDF]

open access: yesAppl Microbiol Biotechnol
Zha J   +19 more
europepmc   +1 more source

Treatment of Pyoderma Gangrenosum With Bimekizumab

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Pyoderma gangrenosum (PG) is an inflammatory neutrophilic dermatosis with no FDA‐approved treatments. Current therapies, including corticosteroids and immunomodulators, often show limited efficacy and nonspecific, conferring to higher risk of adverse events.
Kareena S. Garg   +2 more
wiley   +1 more source

Ecological niche modeling for surveillance of foot-and-mouth disease in South Asia. [PDF]

open access: yesPLoS One
Gunasekera U   +8 more
europepmc   +1 more source

Safety of Baricitinib for the Treatment of Atopic Dermatitis in Adults Over a Median of 1.6 and up to 4.6 Years Treatment: Final Integrated Analysis of Eight Clinical Trials

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Baricitinib is a selective Janus kinase (JAK)1/JAK2 inhibitor approved in more than 70 countries for the treatment of moderate‐to‐severe atopic dermatitis (AD) in adults, and in over 30 countries for adolescents and children from age 2 years with moderate‐to‐severe AD, who are candidates for systemic therapy.
Antonio Costanzo   +11 more
wiley   +1 more source

Atypical Wounds in Chronic Graft‐Versus‐Host Disease and Peripheral Arterial Disease Caused by Tyrosine Kinase Inhibitors

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT The term “atypical wounds” primarily refers to lesions with immunological or cancerous etiologies. However, these wounds can also be drug‐induced. We report about a 32‐year‐old man with a 6‐year history of chronic myelogenous leukemia (CML) and chronic graft‐versus‐host disease (cGvHD) following an HLA‐compatible allogeneic stem cell ...
E. K. Stuermer   +3 more
wiley   +1 more source

Association between ambient air pollution and risk of hand, foot, and mouth disease: a systematic review and meta-analysis. [PDF]

open access: yesBMC Public Health
Hu Q   +10 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy